Podcasts about reachmd

Guest: Jennifer Caudle, DO Host: Patrick McGill, MD Current cancer screening guidelines cover just five cancers—breast, lung, colon, prostate, and cervical—leaving many aggressive cancers undetected until later stages. But multi-cancer early detection (MCED) testing is reshaping the landscape with blood-based analyses of cell-free DNA and methylation patterns to identify potential cancers earlier than traditional imaging. Designed for the general population over age 50, MCED testing complements rather than replaces standard screenings, helping detect cancers at stages when treatment is most effective. Joining Dr. Jennifer Caudle to share practical strategies for integrating MCED into clinical workflows, addressing misconceptions, and streamlining follow-up protocols is Dr. Patrick McGill, board-certified family physician and Executive Vice President, Chief Transformation Officer at Community Health Network in Indianapolis.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Evandro Bezerra, MD As CAR T-cell therapy advances, so does the complexity of adverse event monitoring. Due to evolving insights into acute toxicities, infections, cytopenias, and secondary malignancies, both inpatient and outpatient care models are adapting to meet new standards. Joining Dr. Charles Turck to discuss practical strategies and emerging tools for managing post-CAR T toxicities across the continuum of care is Dr. Evandro Bezerra, Clinical Assistant Professor at Ohio State University Comprehensive Cancer Center in Columbus.

Guest: Marisa McGinley, DO The multiple sclerosis (MS) treatment landscape is rapidly evolving, with novel approaches on the horizon that may transform care for progressive patients. Explore the latest phase 3 data on BTK inhibitors like tolebrutinib and gain insights into ongoing CAR T-cell and remyelination research, including the BEAT-MS trial, with Dr. Marisa McGinley, a neurologist at the Cleveland Clinic.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Neena Abraham, MD, MS Knowing how to manage anticoagulants and antithrombotics during acute GI bleeding is essential in preventing avoidable complications, including thromboembolism and delayed hemostasis. Dr. Peter Buch sits down with Dr. Neena Abraham to discuss the latest recommendations from major GI and cardiology societies and explore practical strategies for anticoagulant reversal, triage criteria, and endoscopic hemostasis. Dr. Abraham is a Professor of Medicine and the Medical Director of the Cardiogastroenterology Clinic at the Mayo Clinic in Phoenix.

Host: Brian P. McDonough, MD, FAAFP Guest: Marie Wood, MD Traditional cancer screening has always focused on individual organs, but now, multi-cancer early detection (MCED) tests are changing that paradigm. By analyzing multiple biomarkers through a single blood draw, MCED testing can detect signals from a variety of cancers—many of which currently lack effective screening tools. These multi-biomarker approaches not only outperform single-marker tests, but also demonstrate scientific rigor and clinical utility. Still, challenges remain, including false positives and integration with standard screening protocols. Joining Dr. Brian McDonough to explore the rationale for using a multi-biomarker approach to MCED testing is Dr. Marie Wood, Professor of Medicine at the University of Colorado School of Medicine and Medical Director of the Hereditary Cancer Program at the CU Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Forat Lutfi, MD Guest: Nilanjan Ghosh, MD, PhD For patients with relapsed/refractory large B-cell lymphoma, timely access to CAR T-cell therapy can be life-saving, but communication gaps between referring physicians and CAR T centers can lead to delays or missed opportunities. Fortunately, practical strategies like building strong referral networks, improving direct communication, and aligning on shared care responsibilities can streamline access and improve outcomes. Joining Dr. Charles Turck to share their insights on how we can bridge these communication gaps are Drs. Forat Lutfi and Nilanjan Ghosh. Dr. Lutfi is an Assistant Professor of Hematologic Malignancies and Cellular Therapeutics at University of Kansas Medical Center, and Dr. Ghosh is a Professor of Cancer Medicine at the Wake Forest University School of Medicine in Charlotte, North Carolina.

Fibrodysplasia ossificans progressiva (FOP) is a severely disabling myopathy in which extraskeletal bone forms and accumulates over time within muscles and soft tissues.1,2 Here's what we know so far about the mechanisms of heterotopic ossification in patients with FOP. References: Kaplan FS et al. Best Pract Res Clin Rheumatol 2008;22:191–205. Pignolo RJ et al. Orphanet J Rare Dis 2011;6:80. © 2025 Ipsen Biopharmaceuticals Inc. All rights reserved. ALLSC-US-001927 | August 2025

Since 2010, the landscape of multiple sclerosis care has transformed to encompass a variety of medications, each having unique benefits, risks, and side effect profiles. Dr. Jonathan Howard discusses how to match treatment strength to disease severity and balance patient risk tolerance with evolving therapeutic options, from long-standing injectables to infusions and oral therapies. Dr. Howard is an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital in New York.

Early symptoms of multiple sclerosis (MS) often present as clear, localized neurological changes lasting several days. However, many nonspecific complaints and common MRI findings can mimic MS, leading to misdiagnosis and unnecessary treatment. Dr. Jonathan Howard, an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital, reviews hallmark symptom patterns, explains how to differentiate benign MRI changes from true disease, and underscores the importance of thorough history-taking, neurological exams, and targeted testing to ensure accurate diagnosis and optimal patient care.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jacqueline Wong, MD, MSCR, FACOG For patients with endometriosis, treatment delays can profoundly impact both quality of life and clinical outcomes. Proactive strategies that address logistical barriers—such as prior authorizations—combined with education and multidisciplinary support are essential in improving care. Join Dr. Charles Turck and Dr. Jacqueline Wong as they explore practical approaches for managing this complex condition and navigating potential hurdles. Dr. Wong is a minimally invasive gynecologic surgeon and an Assistant Professor of Obstetrics and Gynecology in the School of Medicine at Oregon Health and Science University in Portland.

Host: Ryan Quigley Guest: Hallie Blevins, PhD. Guest: Marlene Mimi Maeusli, PhD. With one in three eligible Americans still unscreened for colorectal cancer (CRC), there's an urgent need for noninvasive and affordable alternatives to colonoscopy. A 2025 study published in ACS Sensors introduces a novel aptamer-based colorimetric assay that targets Parvimonas micra—a gut microbe linked to CRC. To learn more, Mr. Ryan Quigley speaks with Drs. Hallie Blevins and Mimi Maeusli about how this technology works, what sets it apart from current testing methods, and why it could play a role in improving early CRC detection. Reference: Feng S, Zhang P, Chen H, et al. Au@Fe3O4 nanoparticle-based colorimetric aptasensor for noninvasive screening of colorectal cancer via detection of Parvimonas micra. ACS Sens. 2025;10(2):1053-1062.

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Fabien Maldonado, MD, FCCP Guest: Adam H. Fox, MD, MSc Cutting-edge biopsy methods and streamlined biomarker testing are transforming early-stage non-small cell lung cancer (NSCLC) care. Hear from Drs. Gerard Silvestri, Fabien Maldonado, and Adam Fox as they discuss the evolution of bronchoscopic techniques, insights from landmark trials, and the role of pragmatic clinical research in refining biopsy approaches. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Maldonado is a Professor of Medicine and Thoracic Surgery, the Pierre Massion Director in Lung Cancer Research, and the Director of Interventional Pulmonology Research at Vanderbilt University; and Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Guest: David Gate, PhD Patients with Alzheimer's disease—especially APOE4 carriers—show distinct epigenetic immune alterations that may influence disease progression, treatment response, and side effect risk. In this episode, Dr. David Gate, an Assistant Professor of Behavioral Neurology at Northwestern University, dives into his research on this subject and explains how chromatin accessibility in proinflammatory genes and T-cell receptor changes link to neurological pathology.

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Jeffrey B. Velotta, MD, FACS Guest: Anne Gonzalez, MD, M.Sc. For patients with non-small cell lung cancer, staging accuracy is critical in guiding treatment decisions that can significantly affect outcomes. In this expert-led discussion, Dr. Gerard Silvestri sits down with Drs. Anne Gonzalez and Jeffrey Velotta break down what clinicians need to know, including how to perform thorough EBUS staging, why PET scans alone aren't enough, and what the updated TNM classification means for surgical planning. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Gonzalez is a pulmonary and critical care physician, a researcher in the Translational Research and Respiratory Diseases Program, and an Associate Professor in the Department of Medicine at McGill University in Montreal; and Dr. Velotta is a leading thoracic surgeon specializing in complex cancers, a Clinical Professor in the Department of Clinical Science at the Kaiser Permanente Bernard J. Tyson School of Medicine, and a Clinical Assistant Professor in the Department of Surgery at UCSF School of Medicine in California. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Rashie Jain for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner!  Rashie is an engineer and Co-Founder of Marvix.AI, her second start-up. Rashie observed that many physicians struggle with high administrative burdens, especially medical specialists who spend more time with patients and deal with complex cases. With the advent of large language models, she created an "ambient scribe" that takes notes during a patient encounter, organizes them, and presents them for review as a finished product. With just a little tweaking, doctors can embed these notes into the electronic medical record (EMR). I tried out Rashie's software at the recent American Academy of Neurology meeting in San Diego, CA. Her Co-Founder played the role of a migraine patient, and we chatted for about 10 minutes. Truth be told, the ambient scribe did a great job capturing the essential details. I could have edited it in just a couple of minutes, which would save time compared to typing it into the EMR myself! To learn more about Marvix.AI, or to try it in your own office, please contact Rashie Jain at https://www.marvixapp.ai#AI #ambientscribe #largelanguagemodel #womenentrepreneurPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

Immune imprinting refers to how the immune system's first encounter with a virus, such as influenza, leaves a lasting imprint that shapes future immune responses.1,2 However, influenza vaccines may affect this process—particularly when egg-based ones are used. Tune in to learn about the impact of immune imprinting, the role that vaccines play in this process, and how switching to non-egg-based vaccines could help redirect immune responses and possibly create more effective defenses in people of all ages.3,4 References: King SM, Bryan SP, Hilchey SP, Wang J, Zand MS. First impressions matter: Immune imprinting and antibody cross-reactivity in influenza and SARS-CoV-2. Pathogens. 2023;12(2):169. doi:10.3390/pathogens12020169 Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original antigenic sin: How first exposure shapes lifelong anti-influenza virus immune responses. J Immunol. 2019;202(2):335–340. doi:10.4049/jimmunol.1801149 Rockman S, Laurie K, Ong C, et al. Cell-based manufacturing technology increases antigenic match of influenza vaccine and results in improved effectiveness. Vaccines (Basel). 2022;11(1):52. doi:10.3390/vaccines11010052 Liu F, Gross FL, Jefferson SN, et al. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination. J Clin Invest. 2021;131(8):e146138. doi:10.1172/JCI146138 USA-CRP-24-0038 July 2025

Guest: Ariel Cerenzie, OD, FAAO, FSLS Dr. Ariel Cerenzie shares quick tips on how she communicates the urgency of myopia progression to parents and introduces MiSight® 1 day as a proactive solution. She explains that the lenses not only correct vision but also therapeutically slow myopia progression, offering a meaningful way to protect a child's long-term eye health.

Guest: Sheila Morrison, OD, MS, FSLS In this short video, Dr. Shelia Morrison explains how she introduces parents to myopia management by emphasizing that today's treatment options—like MiSight® 1 day—can both correct vision and slow myopia progression during critical growth periods. She highlights the importance of early intervention and presents daily disposable lenses as a safe, effective solution for active children.

Host: Jennifer Caudle, DO Guest: Blen Girmay, MD Because standard-dose vaccines usually produce only modest immunogenic responses in people age 65 years and older, the Advisory Committee on Immunization Practices, as of June 2022, recommended this age group receive either an adjuvanted or higher-dose seasonal influenza vaccine.1,2,3 A pragmatic, head-to-head randomized study compared FLUAD and the high-dose influenza vaccine over the course of two influenza seasons.2 Joining Dr. Jennifer Caudle to discuss this study and its findings from the first season (2023-2024) is Dr. Blen Girmay, a Johns Hopkins fellowship-trained primary care geriatrician at Inova Health System in Fairfax, Virginia. References: Coleman BL, Sanderson R, Haag MDM, McGovern I. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses. 2021;15(6):813-823. Klein N. Oral presentation presented at: IDWeek 2024 Meeting; October 16-19, 2024. Los Angeles, CA. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. MMWR Recomm Rep. 2024;73(5):1-25.

Guest: Eric Ritchey, OD, PhD, FAAO Listen to Dr. Eric Ritchey explain how he introduces MiSight® 1 day to parents—highlighting its safety, comfort, and dual benefits—and emphasizes the importance of daily disposables for hygiene and the long-term eye health advantages of managing myopia early in children.

Host: Matt Birnholz, MD Guest: Jim Foote, MBA Functional precision medicine is reshaping oncology by integrating real-time drug testing, genomic data, and artificial intelligence to guide individualized treatment. Dr. Matt Birnholz sits down with Jim Foote, CEO of First Ascent Biomedical, to explore how this approach delivers clinically actionable insights for relapsed and resistant cancer and empowers oncologists with faster, more targeted decision making.

Host: Jennifer Caudle, DO Guest: Johanna Finkle, MD, FACOG As GLP-1 therapies grow in popularity for weight management and diabetes, an unexpected consequence has emerged: a rise in unplanned pregnancies due to reduced oral contraceptive effectiveness. Dr. Jennifer Caudle sits down with Dr. Johanna Finkle, a weight loss specialist and OB/GYN at the University of Kansas Health System, to explore the mechanisms behind this trend and outline practical, long-acting contraceptive alternatives that maintain efficacy during GLP-1 use.

Guest: Ashley Tucker, OD, FAAO, FSLS, Dipl ABO In this short video, Dr. Ashley Tucker shares how she talks to parents about myopia management, emphasizing that myopia is more than just blurry vision; it's a progressive condition that can lead to serious eye health risks. She introduces MiSight® 1 day as a dual-purpose option that not only corrects vision, but also helps slow the progression of myopia in age-appropriate children.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35988/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35989/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35985/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35987/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35990/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35986/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35991/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35992/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

CME credits: 1.00 Valid until: 11-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/program-name/35993/ Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.

Guest: Mateo Mejia Saldarriaga, M.D. Mateo Mejia Saldarriaga, M.D., a hematologist/oncologist at NewYork-Presbyterian and Weill Cornell Medicine, explains how he and his team conducted a retrospective study that identified a biomarker to enhance treatment planning for BCMA CAR T-cell therapy in multiple myeloma. By measuring absolute lymphocyte count (ALC) through a routine CBC 15 days after a CAR T-cell therapy injection, they found patients with an ALC > 1,000 had a median progression-free survival (PFS) of 30 months whereas patients with an ALC ≤ 500 had a median PFS of 6 months. This new biomarker is now being leveraged to help doctors predict whether a patient is benefiting from treatment in as early as 15 days. © 2025 NewYork-Presbyterian

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and emerging PIK3CA-targeted therapies, Dr. Charles Turck speaks with Dr. Neil Iyengar, Co-Director of the Breast Oncology Program and Director of Cancer Survivorship Service at Winship Cancer Institute at Emory University.

Guest: Brian Slomovitz, MD Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise. Dr. Brian Slomovitz highlights future directions that could redefine treatment pathways for patients with advanced or recurrent disease. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there's a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it's also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it's important to know how and when to test for this mutation and how emerging targeted therapies might change our approach in clinical practice. Joining Dr. Charles Turck to share her insights on PI3Kα testing and targeted therapies for HR+/HER2- advanced breast cancer is Dr. Hope Rugo, Director of the Women's Cancers Program, Division Chief of Breast Medical Oncology and Professor of the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.

Guest: Brian Slomovitz, MD Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise. Dr. Brian Slomovitz highlights future directions that could redefine treatment pathways for patients with advanced or recurrent disease. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there's a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and emerging PIK3CA-targeted therapies, Dr. Charles Turck speaks with Dr. Neil Iyengar, Co-Director of the Breast Oncology Program and Director of Cancer Survivorship Service at Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it's also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it's important to know how and when to test for this mutation and how emerging targeted therapies might change our approach in clinical practice. Joining Dr. Charles Turck to share her insights on PI3Kα testing and targeted therapies for HR+/HER2- advanced breast cancer is Dr. Hope Rugo, Director of the Women's Cancers Program, Division Chief of Breast Medical Oncology and Professor of the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the Division of Hematology/Oncology at the University of Nebraska Medical Center.

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Brenda Snow for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner!  Brenda is the Founder and CEO of Snow Companies, which helps engage patients with their healthcare services. Her own life-changing experience with a neurologic disorder, which she experienced as an "identity earthquake," triggered the creation of her business, "Snow Companies." Thirty years ago, Brenda suffered from unexplained symptoms including double vision, dragging her left foot, loss of bladder control, and strange fatigue. After initial misadventures with a couple of neurologists, she was accurately diagnosed with multiple sclerosis. Brenda eventually discovered a supportive medical team. She takes regular multiple sclerosis treatments, maintains a healthy lifestyle, and lives an active and successful life. Brenda started "Snow Companies" nearly 25 years ago. Now with over 400 employees, Snow Companies helps pharmaceutical companies engage with their patients. Brenda also hopes to help patients with her new book, "Diagnosed: The Essential Guide to Navigating the Patient's Journey." Brenda graciously offered to send a free, signed copy of her book to anyone who can't afford it. Just send her an email through her website: https://brendasnow.com #multiple sclerosis #womenentrepreneurs #entrepreneurs #authorPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

Guest: Abiodun Ologunowa Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shifts, but gaps still remain in how children receive essential medications. Joining Dr. Charles Turck to discuss these national prescribing trends, disparities in care, and the implications of evolving treatment guidelines for this population is Dr. Abiodun Ologunowa. Dr. Ologunowa is a doctoral candidate and research assistant in the Department of Pharmacy Practice and Clinical Research at the University of Rhode Island College of Pharmacy.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Whitney Trotter Ross, MD, MSCI Despite advances in endometriosis treatment, bias and stigma continue to delay diagnosis and disrupt care for many patients. Informed, empathetic care is key for supporting diverse patient populations. Dr. Charles Turck sits down with Dr. Whitney Ross to unpack how historical misconceptions still influence prescribing habits and discuss actionable strategies for counseling, selecting a treatment plan, and building trust. Dr. Ross is an Assistant Professor of Obstetrics and Gynecology in the Division of Minimally Invasive Gynecologic Surgery at Washington University in St. Louis.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Whitney Trotter Ross, MD, MSCI Despite advances in endometriosis treatment, bias and stigma continue to delay diagnosis and disrupt care for many patients. Informed, empathetic care is key for supporting diverse patient populations. Dr. Charles Turck sits down with Dr. Whitney Ross to unpack how historical misconceptions still influence prescribing habits and discuss actionable strategies for counseling, selecting a treatment plan, and building trust. Dr. Ross is an Assistant Professor of Obstetrics and Gynecology in the Division of Minimally Invasive Gynecologic Surgery at Washington University in St. Louis.

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Matt Holgotz-Hetling for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner! Matt is a journalist and author of "If it Sounds Like a Quack…" His prior book, "A Libertarian Walks into a Bear," received 4.5 stars on Amazon and more than 1,000 reviews. During COVID, Matt took an interest in two conflicting forces he observed in American society. On the one hand, public health officials were trying to protect the public by recommending masks and closing schools. On the other hand, many independent-minded Americans insisted on making their own decisions, often eschewing masks and social distancing.  Matt was intrigued by fringe practitioners offering cures for COVID, which included baking soda, bleach, lasers, and leeches. Many alternative medicine practitioners had faith in their "One True Cure." Of course, it was difficult to eliminate greed and exploitation as supporting motivations. Matt and I had an in-depth conversation for nearly an hour! It was a treat to speak with such an informed and thoughtful author. Matt's newest book, "The Ghost Lab," should be available shortly. You can find all of Matt's books on Amazon. To learn more, please check out Matt's website:https://www.matt-hongoltzhetling.com#concussion #CTE #traumatic brain injury #TBI Please click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...